专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130224109A1 COMPOSITIONS AND METHODS FEATURING IL-6 AND IL-21 ANTAGONISTS 审中-公开
标题翻译：特征IL-6和IL-21拮抗剂的组合物和方法
公开(公告)号：US20130224109A1
公开(公告)日：2013-08-29
申请号：US13810956
申请日：2011-07-20
申请人： Terry Strom , Maria Koulmanda
发明人： Terry Strom , Maria Koulmanda
IPC分类号： A61K39/395 , C07K16/46
CPC分类号： A61K39/3955 , A61K38/20 , A61K45/06 , C07K14/54 , C07K16/248 , C07K16/468 , C07K2317/76 , C07K2319/30 , A61K2300/00
摘要： The present invention features compositions for inhibiting both the IL-6 and the IL-21 pathways and methods of making and using such compositions. Our work to date indicates the importance of the redundancy of IL-6 and IL-21 to perform certain crucial functions. The pathways can be inhibited by inhibiting the ligands (i.e., IL-6 and IL-21) and/or their respective receptors (i.e., the IL-6 receptor and IL-21 receptor). Alternatively, or in addition, upstream and downstream effectors in the IL-6 and IL-21 pathways can be blocked. The agents used can be antibody or antibody-based proteins or peptides including circulating receptors, optionally coupled to an immunoglobulin or a portion thereof (e.g., the Fc region). Also provided are methods for using the compositions, for example, in organ transplantation, tissue grafting, or autoimmune disorders.
摘要翻译：本发明的特征在于抑制IL-6和IL-21途径的组合物以及制备和使用这些组合物的方法。我们迄今为止的工作表明，IL-6和IL-21的冗余对于执行某些关键功能的重要性。可通过抑制配体（即IL-6和IL-21）和/或它们各自的受体（即IL-6受体和IL-21受体）来抑制途径。或者或另外，可以阻断IL-6和IL-21途径中的上游和下游效应物。使用的药剂可以是抗体或基于抗体的蛋白质或包括任选与免疫球蛋白或其部分（例如，Fc区）偶联的循环受体）的肽。还提供了使用组合物例如器官移植，组织移植或自身免疫疾病的方法。

2. 发明申请

US20080008680A1 Antagonists of interleukin-15 有权
标题翻译：白细胞介素15的拮抗剂
公开(公告)号：US20080008680A1
公开(公告)日：2008-01-10
申请号：US11726086
申请日：2007-03-20
申请人： Terry Strom , Wlodzimierz Maslinski
发明人： Terry Strom , Wlodzimierz Maslinski
IPC分类号： A61K38/20 , A61P25/28 , A61P29/00 , C07H21/04 , C07K14/54 , C12N5/00 , G01N33/566 , G01N33/567
CPC分类号： G01N33/6869 , A61K38/00 , C07K14/5443 , C07K2319/00 , Y10S514/825
摘要： Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.
摘要翻译：本文公开了突变型IL-15多肽和使用这些多肽调节患者免疫应答的方法。

3. 发明申请

US20080089894A1 Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis 审中-公开
标题翻译：通过共刺激阻断和T细胞活化诱导的凋亡的移植耐受
公开(公告)号：US20080089894A1
公开(公告)日：2008-04-17
申请号：US11999412
申请日：2007-12-05
申请人： Terry Strom , Xin Xiao Zheng
发明人： Terry Strom , Xin Xiao Zheng
IPC分类号： A61K39/395 , A61K31/436 , A61P37/06
CPC分类号： A61K31/4745 , A61K31/436 , A61K35/60 , A61K39/39541 , A61K2039/505 , C07K16/2875 , A61K2300/00
摘要： The invention relates to methods of inducing tolerance and preventing transplant rejection by blocking costimulatory signals and using immunosuppressive agents, preferably rapamycin, to prevent late rejection episodes, yet not block tolerance inducing T-cell specific depletion; compositions and kits for use in such methods are also provided herein.
摘要翻译：本发明涉及通过阻断共刺激信号并使用免疫抑制剂（优选雷帕霉素）来预防晚期排斥发作，但不阻止诱导T细胞特异性消耗的耐受性来诱导耐受性和预防移植排斥的方法; 本文还提供了用于此类方法的组合物和试剂盒。

4. 发明申请

US20070122806A1 Predicting graft rejection 有权
标题翻译：预测移植排斥反应
公开(公告)号：US20070122806A1
公开(公告)日：2007-05-31
申请号：US10545198
申请日：2004-02-17
申请人： Terry Strom , Towia Libermann , Asher Schachter
发明人： Terry Strom , Towia Libermann , Asher Schachter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , G06F19/00 , Y02A90/26
摘要： The present invention features prognostic methods useful in assessing patients who have received a transplant and reagents, optionally packaged as kits or organized as arrays, that can be used to carry out those methods. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, such as the age of the donor. The clinical parameters include one or more variables associated with the recipient (e.g., the recipient's age and/or race); one or more variables associated with the graft (e.g., whether the graft is obtained from a living donor or a cadaver and the ischemic time); and variables associated with the donor (e.g., the donor's age and/or race). The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes below as “inflammatory”, “immune” or “cytoprotective”). Surprisingly, we found that the levels of gene expression could predict the occurrence of DGF, AR, and the quality of later graft function even when analyzed shortly after the transplant was performed (e.g., shortly after vascular anastomosis and tissue reperfusion). We also found that clinical parameters available at the time of transplantation correlate with decreased graft health and can be considered in combination with gene expression to evaluate a patient's risk for an adverse outcome.
摘要翻译：本发明具有用于评估已经接受移植的患者的预后方法和可以用于实施这些方法的试剂，可选地包装为试剂盒或组织为阵列。本发明部分基于我们对肾同种异体移植物中基因表达和临床参数的分析，如供体的年龄。临床参数包括与接收者相关联的一个或多个变量（例如，接收者的年龄和/或种族）; 与移植物相关联的一个或多个变量（例如，移植物是从活体供体或尸体获得的以及缺血时间）; 和与供体相关联的变量（例如，捐赠者的年龄和/或种族）。可以评估的基因包括介导炎症，免疫激活和细胞死亡的编码剂（我们可以将这些基因称为“炎症”，“免疫”或“细胞保护”）。令人吃惊的是，即使在进行移植后（例如血管吻合术和组织再灌注后不久），基因表达水平也能够预测DGF，AR的发生以及晚期移植物功能的质量。我们还发现移植时可用的临床参数与移植物健康状况有关，可以与基因表达相结合，以评估患者的不良结局风险。

5. 发明申请

US20050058624A1 Chimeric IL-10 proteins and uses thereof 审中-公开
标题翻译：嵌合IL-10蛋白及其用途
公开(公告)号：US20050058624A1
公开(公告)日：2005-03-17
申请号：US10910257
申请日：2004-08-02
申请人： Terry Strom , Xin Zheng , Alan Steele
发明人： Terry Strom , Xin Zheng , Alan Steele
IPC分类号： A61K38/00 , C07K14/52 , C07K16/46 , C12N15/24 , C12N15/62 , A61K38/48 , A61K38/20 , A61K39/395
CPC分类号： A61K38/2026 , A61K38/2066 , A61K38/38 , A61K38/45 , C07K14/52 , C07K16/46 , C07K2317/71 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/75 , C12N15/62 , Y02A50/423 , Y10S514/866 , A61K2300/00
摘要： Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
摘要翻译：公开了具有IL-10融合到酶促无活性多肽的嵌合蛋白，其增加IL-10的循环半衰期。嵌合多肽可用于治疗或预防败血性休克，抑制I型糖尿病的发展和治疗患者的多发性骨髓瘤。

6. 发明申请

US20070082356A1 Methods of evaluating transplant rejection 审中-公开
标题翻译：评估移植排斥的方法
公开(公告)号：US20070082356A1
公开(公告)日：2007-04-12
申请号：US11541912
申请日：2006-10-02
申请人： Terry Strom , Manikkam Suthanthiran , Lauro Vasconcellos
发明人： Terry Strom , Manikkam Suthanthiran , Lauro Vasconcellos
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158
摘要： The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.
摘要翻译：本发明涉及评估宿主中移植排斥反应的方法，其包括确定排斥相关基因簇中基因的基因表达的增加的程度。所公开的基因簇包括与细胞毒性淋巴细胞促凋亡基因，细胞保护基因和若干其它细胞因子和免疫细胞基因基本共表达的基因。

7. 发明申请

US20060057680A1 Mutant interleukin-15 polypeptides 审中-公开
标题翻译：突变型白细胞介素-15多肽
公开(公告)号：US20060057680A1
公开(公告)日：2006-03-16
申请号：US11201585
申请日：2005-08-11
申请人： Xin Zheng , Terry Strom , Thomas Moll
发明人： Xin Zheng , Terry Strom , Thomas Moll
IPC分类号： C07K14/54 , C07H21/04 , C12P21/04
CPC分类号： A61K38/2086 , A61K39/39541 , C07K14/5443 , C07K2319/30 , A61K2300/00
摘要： Mutant IL-15 polypeptides and compositions including the polypeptides are described herein. In various embodiments, a mutant IL-15 polypeptide is joined to a heterologous polypeptide. Also described herein are uses of the mutant IL-15 polypeptides, e.g., in suppressing immune responses.
摘要翻译：本文描述了突变IL-15多肽和包含多肽的组合物。在各种实施方案中，突变的IL-15多肽与异源多肽连接。本文还描述了突变IL-15多肽的用途，例如抑制免疫应答。

8. 发明授权

US06281193B1 Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same 失效
标题翻译：抑制RAF-1或14-3-3蛋白与IL-2受体的β链的结合的化合物和含有其的药物组合物
公开(公告)号：US06281193B1
公开(公告)日：2001-08-28
申请号：US09194145
申请日：1999-03-08
申请人： Terry Strom , Wlodzimierz Maslinski
发明人： Terry Strom , Wlodzimierz Maslinski
IPC分类号： A61K3820
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4705 , C07K14/7155 , C12Q1/485 , G01N33/6869 , G01N2500/04 , Y10S424/81
摘要： The invention relates to compounds, such as proteins, peptides and organic compounds, capable of blocking or inhibiting the binding interaction of Raf-1 or 14-3-3 proteins to the &bgr; chain of IL-2, and pharmaceutical compositions containing such compounds. In vitro assays for isolating, identifying and characterizing such compound capable of inhibiting interaction of Raf-1 or 14-3-3 proteins to IL-2&bgr; are also provided.
摘要翻译：本发明涉及能够阻断或抑制Raf-1或14-3-3蛋白与IL-2的β链的结合相互作用的化合物，例如蛋白质，肽和有机化合物，以及含有这些化合物的药物组合物。还提供了用于分离，鉴定和表征能够抑制Raf-1或14-3-3蛋白与IL-2beta相互作用的化合物的体外测定。

9. 发明授权

US08329660B2 Tim-3 ligands and methods thereof 有权
标题翻译： Tim-3配体及其方法
公开(公告)号：US08329660B2
公开(公告)日：2012-12-11
申请号：US10958169
申请日：2004-10-04
申请人： Vijay K. Kuchroo , Terry Strom , Eugene K. Cha , Sumone Chakravarti , Catherine Sabatos , Chen Zhu , Xin Xiao Zheng , Alberto Sanchez-Fueyo
发明人： Vijay K. Kuchroo , Terry Strom , Eugene K. Cha , Sumone Chakravarti , Catherine Sabatos , Chen Zhu , Xin Xiao Zheng , Alberto Sanchez-Fueyo
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , C07K14/4713 , C07K14/70503 , C07K16/28 , C07K2319/30 , G01N33/505
摘要： The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
摘要翻译：本发明涉及分离的多肽和编码多肽的核酸，其包含tim-3 IgV结构域和tim-3细胞内结构域，其中所述多肽不包含tim-3粘蛋白结构域或tim-3跨膜结构域。此外，本发明涉及调节受试者中的免疫应答的方法，包括向受试者施用治疗有效量的调节tim-3活性的药剂。免疫反应包括但不限于免疫耐受性，移植耐受性，Th1应答和Th2应答。

10. 发明授权

US07741271B2 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function 有权
标题翻译：通过调节tim-1，tim-2和tim-4功能来调节免疫应答的方法
公开(公告)号：US07741271B2
公开(公告)日：2010-06-22
申请号：US11080091
申请日：2005-03-14
申请人： Vijay K. Kuchroo , Sumone Chakravarti , Terry Strom , Xin Xiao Zheng , Jennifer Meyers
发明人： Vijay K. Kuchroo , Sumone Chakravarti , Terry Strom , Xin Xiao Zheng , Jennifer Meyers
IPC分类号： A61K38/00 , A61K45/00 , A61K47/00
CPC分类号： C07K16/2803 , A61K38/00 , A61K38/177 , A61K39/39541 , A61K39/3955 , A61K48/00 , A61K2039/505 , C07K14/70503 , C07K16/2875 , C07K2319/00 , C12N2310/14 , G01N33/5768 , G01N33/6812 , G01N33/6845 , G01N33/6863 , G01N33/6872 , G01N2500/02 , G01N2800/24 , A61K2300/00
摘要： The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
摘要翻译：本发明涉及调节受试者的免疫应答的方法，例如通过施用调节tim-1，tim-2或tim-4活性或调节tim-1和tim-4之间的物理相互作用的受试者或在tim-2和tim-2配体之间。免疫反应包括但不限于自身免疫性疾病，移植耐受性和Th1和Th2介导的应答和障碍。本发明还涉及用于鉴定调节tim-1和tim-4之间的物理相互作用的试剂的新型测定法。此外，本发明涉及新的可溶性tim-4多肽和编码它们的核酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式